Kairos Pharma Ltd (KAPA) FinancialsKAPAKairos Pharma Ltd

Evaluating the bottom line, Kairos Pharma Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -113.96%, provide a clear picture of how effectively KAPA converts its operational activities into shareholder value.

In the context of the broader market, KAPA competes directly with industry leaders such as NIKI and LIMN. With a market capitalization of $5.62M, it holds a significant position in the sector. When comparing efficiency, KAPA's gross margin of N/A stands against NIKI's N/A and LIMN's N/A. Such benchmarking helps identify whether Kairos Pharma Ltd is trading at a premium or discount relative to its financial performance.

KAPA has consistently reported negative net income, with the latest figure being -1,654,000 USD for Q1 2026. The EPS has also been negative, with a reported EPS of -0.08 in Q1 2026. The company's current ratio is strong at 10.31, indicating good short-term liquidity, but the overall financial performance is concerning due to ongoing losses.